Want to see UNCY full AI Analyst Report?
UNCY Stock Chart & Stats
$5.47
$0.03(0.56%)
At close: 4:00 PM EDT
$5.47
$0.03(0.56%)
Day’s Range― - ―
52-Week Range$3.35 - $8.74
Previous CloseN/A
Volume52.73K
Average Volume (3M)1.00M
Market Cap
$108.36M
Enterprise Value$65.55M
Total Cash (Recent Filing)$61.42M
Total Debt (Recent Filing)$671.00K
Price to Earnings (P/E)―
Beta1.60
Next Earnings
Nov 18, 2026EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.67
Shares Outstanding27,855,257
10 Day Avg. Volume1,142,297
30 Day Avg. Volume1,004,812
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)3.04
Price to Sales (P/S)0.00
P/FCF Ratio-2.92
Enterprise Value/Market Cap0.60
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-310.69
Enterprise Value/Ebitda-1.90
Forecast
1Y Price Target
$25.50Price Target Upside366.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.25
Revenue Forecast (FY)$412.88K
Bulls Say, Bears Say
Bulls Say
Regulatory ProgressResubmission with a new FDA-rated manufacturing vendor directly addresses deficiencies cited in prior CRLs, while stability and bridging data support the revised filing. This improves regulatory execution and preserves a path toward commercialization, although approval is not assured.
Balance Sheet RepairVery low debt relative to equity gives Unicycive limited leverage exposure and greater flexibility while advancing its lead program. The recovery from previously negative equity also indicates meaningful balance-sheet repair, helping support operations before potential commercialization.
Funding RunwayReported cash and securities provide funding capacity for continued regulatory work and commercial launch preparation over the next several quarters. This runway can reduce immediate financing pressure and allow management to execute the oxylanthanum carbonate program without relying solely on near-term capital access.
Bears Say
No Current RevenueThe absence of current revenue confirms that Unicycive remains dependent on successful development and eventual commercialization of its pipeline. Persistent large losses also show that the business has not yet demonstrated operating leverage, making future earnings highly contingent on regulatory and launch execution.
Persistent Cash BurnContinued operating and free-cash-flow losses consume resources while the company remains pre-commercial. Even though burn improved from 2025, ongoing negative cash generation creates a durable need to manage spending carefully and may require additional financing if revenue does not begin to ramp.
Litigation OverhangThe securities lawsuit adds legal and reputational uncertainty while Unicycive is pursuing approval for its lead therapy. Although the company rejects the allegations and no outcome is determined, the dispute can distract management and complicate stakeholder confidence during a pivotal regulatory period.
Unicycive Therapeutics News
UNCY FAQ
What was Unicycive Therapeutics’s price range in the past 12 months?
Unicycive Therapeutics lowest stock price was $3.35 and its highest was $8.74 in the past 12 months.
What is Unicycive Therapeutics’s market cap?
Unicycive Therapeutics’s market cap is $108.36M.
When is Unicycive Therapeutics’s upcoming earnings report date?
Unicycive Therapeutics’s upcoming earnings report date is Nov 18, 2026 which is in 24 days.
How were Unicycive Therapeutics’s earnings last quarter?
Unicycive Therapeutics released its earnings results on Aug 12, 2026. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.471 by $0.411.
Is Unicycive Therapeutics overvalued?
According to Wall Street analysts Unicycive Therapeutics’s price is currently Undervalued.
Does Unicycive Therapeutics pay dividends?
Unicycive Therapeutics does not currently pay dividends.
What is Unicycive Therapeutics’s EPS estimate?
Unicycive Therapeutics’s EPS estimate is -0.35.
How many shares outstanding does Unicycive Therapeutics have?
Unicycive Therapeutics has 27,855,257 shares outstanding.
What happened to Unicycive Therapeutics’s price movement after its last earnings report?
Unicycive Therapeutics reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.471. Following the earnings report the stock price went up 7.8%.
Which hedge fund is a major shareholder of Unicycive Therapeutics?
Currently, no hedge funds are holding shares in UNCY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Unicycive Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.50 (366.18% Upside)
$25.50 (366.18% Upside)
Blogger Sentiment
Bullish
UNCY Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 263.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-19.95%
12-Months-Change
Fundamentals
Return on Equity
-88.81%
Trailing 12-Months
Asset Growth
140.14%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Unicycive Therapeutics
Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.
UNCY Stock 12 Month Forecast
Average Price Target
$25.50
▲(366.18% Upside)
Technical Analysis
Ownership Overview
9.85%
Insiders
3.56% Mutual Funds
20.78% Other Institutional Investors
56.84% Public Companies and
Individual Investors